Disclaimer

This site contains medical information that is intended for residents of the United States only and is not meant to be a substitute for the advice provided by a medical professional. Always consult a healthcare provider if you have health concerns. For residents outside of the US, please go to www.merckserono.net for information.

EMD Serono, Inc.
EMD Serono building

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, is a leader in the US biopharmaceutical arena, integrating cutting-edge science with unparalleled patient support systems to improve people's lives. The company has strong market positions in neurodegenerative diseases, with Rebif® (interferon beta-1a), as well as in endocrinology, with Saizen® (somatropin (rDNA origin) for injection), Serostim® (somatropin (rDNA origin) for injection) and Zorbtive™ (somatropin (rDNA origin) for injection). EMD Serono is a leader in fertility treatments, with Gonal-f® (follitropin alpha for injection), Luveris® (lutropin alfa for injection) and Ovidrel® Prefilled Syringe (choriogonadotropin alpha injection). With a clear focus on the patient and a leadership presence in the biopharmaceutical industry, EMD Serono’s US footprint continues to grow, with more than 850 employees around the country and fully integrated commercial, clinical and research operations in the company’s home state of Massachusetts.
        © 2008 EMD Serono, Inc.

        Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.

        Last updated: 5/28/2008